Intervacc and the Karolinska Institutet extend contract for the development of innovative animal health vaccines

Stockholm 15 June 2020 - Intervacc AB (publ) and the Karolinska Institute, KI, announce today that they have extended the contract for the development of a new generation of animal health vaccines using recombinant proteins. The extended contract means that the research group at Karolinska Institutet, led by Professor Birgitta Henriques Normark, is expanded and continues to be part of the already very successful collaboration between KI, the Swedish University of Agriculture (SLU) and Intervacc. This collaboration has led to the development of Strangvac, an innovative new vaccine against strangles, a highly contagious and serious infection in horses. The agreement includes the continued development of two other vaccine projects with great potential to bring modern vaccine technology into the animal health sector.

It is very positive that we can attract a recognized research team led by Professor Birgitta Henriques Normark who has many years of experience in bacteriological research and vaccine development. A contribution that will be of great importance for our ongoing vaccine development projects” says Professor Jan-Ingmar Flock Chief Scientific Officer at Intervacc.

"We are really pleased to be able to continue to collaborate with a recognized research team led by Professor Birgitta Henriques Normark. Intervacc is very pleased with the results that our research teams at KI and SLU have achieved together. We are at the forefront of some very innovative animal health vaccine technologies and we are excited about the ability to utilize this knowledge within vaccinology to bring new animal health vaccines to the market" says Andreas Andersson, CEO Intervacc AB.Professor Birgitta Henriques Normark at Karolinska Institutet, “I’m very pleased with the cooperation with Intervacc and we are excited to continue the work together with the development team. Together we are a leader in developing vaccines using fusions of recombinant proteins, and we believe firmly that we are only in the beginning of this expanding field. This agreement confirms Intervacc and KI’s long-term commitment to the project.”

Intervacc’s research pipeline, in addition to Strangvac, includes two vaccine projects. One project against Streptococcus suis infections in piglets that leads to potentially lethal meningitis and a second project against Staphylococcus aureus infections in dairy cows , which results in intractable mastitis.

Streptococcus suis causes severe infections in some pig herds with devastating results for the pig industry. There are almost one billion pigs worldwide and the need for a working vaccine is in great demand.  Vaccine development is also a crucial tool for reducing the widespread resistance of antibiotics a global threat of great concern.

For more information please contact:                    

Andreas Andersson, CEO
Phone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on June 15, 2020, 09.45 CET.

About Intervacc

Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

About Karolinska Institutet

Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. Visit the website at http://ki.se/

About SLU the Swedish University of Agricultural Sciences

SLU, the Swedish University of Agricultural Sciences, is a world-class international university with research, education and environmental assessment within the sciences for sustainable life. Its principal sites are in Alnarp, Umeå and Uppsala, but activities are also conducted at research stations, experimental parks and educational establishments throughout Sweden. We bring together people who have different perspectives, but they all have one and the same goal: to create the best conditions for a sustainable, thriving and better world. Please visit the website http://www.slu.se/ for more information.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

About Us

Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Subscribe

Media

Media

Documents & Links

Quotes

I’m very pleased with the cooperation with Intervacc and we are excited to continue the work together with the development team. Together we are a leader in developing vaccines using fusions of recombinant proteins, and we believe firmly that we are only in the beginning of this expanding field. This agreement confirms Intervacc and KI’s long-term commitment to the project.
Professor Birgitta Henriques Normark, Karolinska Institutet
We are really pleased to be able to continue to collaborate with a recognized research team led by Professor Birgitta Henriques Normark. Intervacc is very pleased with the results that our research teams at KI and SLU have achieved together. We are at the forefront of some very innovative animal health vaccine technologies and we are excited about the ability to utilize this knowledge within vaccinology to bring new animal health vaccines to the market
Andreas Andersson, CEO Intervacc AB